Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8.

Structure (London, England : 1993) - 1 Feb 2008

Li Shiqing, Kussie Paul, Ferguson Kathryn M

Abstract excerpt

Therapeutic anticancer strategies that target and inactivate the epidermal growth factor receptor (EGFR) are under intense study in the clinic. Here we describe the mechanism of EGFR inhibition by an antibody drug IMC-11F8. IMC-11F8 is a fully human antibody that has similar antitumor potency as the chimeric cetuximab/Erbitux and might represent a safer therapeutic alternative. We report the X-ray crystal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized
Share to Cetuximab

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Crystallography, X-Ray

Share to Epitopes

Share to ErbB Receptors

Share to Glycosylation

Share to Immunoglobulin Fab Fragments

Source

Identifiers

PMID: 18275813
DOI: 10.1016/j.str.2007.11.009

Genes

EGFR
EGF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8.PMID 18275813Read ↗

Analysis of EGFR binding hotspots for design of new EGFR inhibitory biologicsSemantic proximity Read ↗

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.Semantic proximity Read ↗

Inhibiting epidermal growth factor receptor at a distance.Semantic proximity Read ↗

Structure and clinical relevance of the epidermal growth factor receptor in human cancer.Semantic proximity Read ↗

Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation.Semantic proximity Read ↗

[Experimental and computational analyses of altered cetuximab binding induced by EGFR mutations].Semantic proximity Read ↗

High Affinity Promotes Internalization of Engineered Antibodies Targeting FGFR1Semantic proximity Read ↗

Molecular Basis for Necitumumab Inhibition of EGFR Variants Associated with Acquired Cetuximab ResistanceSemantic proximity Read ↗

Toward structure-based drug design against the epidermal growth factor receptor (EGFR).Semantic proximity Read ↗

The insulin and EGF receptor structures: new insights into ligand-induced receptor activation.Semantic proximity Read ↗

X-ray Structures of the Antigen-binding Domains from Three Variants of Humanized anti-p185HER2 Antibody 4D5 and Comparison with Molecular ModelingSemantic proximity Read ↗

Structural basis of antibody inhibition and chemokine activation of the human CC chemokine receptor 8Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.